Aqua Bio Technology ASA: Preliminary results of the Subsequent Offering

20 Mar 2026 15:20 CET

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR
INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED
STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR
DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER
OF ANY OF THE SECURITIES DESCRIBED HEREIN

Reference is made to the stock exchange announcement by Aqua Bio Technology
ASA ("ABTEC" or the "Company") on 12 March 2026 regarding the start of the
subscription period in a subsequent offering of up to 800,000 new shares (the
"Offer Shares"), each at a subscription price of NOK 5.00 (the "Subsequent
Offering").

The Subscription Period expired yesterday, 19 March 2026, at 16:30 hours
(CET). The Company has been informed by our settlement agent that at the end
of the Subscription Period, and based on a preliminary count, valid
subscriptions had been received for a total of 388,240 Offer Shares.

The final result of the Subsequent Offering is expected to be announced by the
Company on or about 23 March 2026. Investors that are allocated Offer Shares
can access information on the number of Offer Shares allocated through VPS on
or about 23 March 2026. Further announcements in respect of the Subsequent
Offering and the Offer Shares will be made in due course.

The due date for payment of the Offer Shares is on 25 March 2026. Subject to
due payment of the Offer Shares by the subscribers, the share capital increase
relating to the Subsequent Offering will be registered with the Norwegian
Register of Business Enterprises, and the Offer Shares will thereafter be
delivered to the VPS accounts of the allocated subscribers on or about 8 April
2026. The Offer Shares will be delivered as listed and tradable shares. First
day of trading of the Offer Shares on Euronext Expand is expected on or about
8 April 2026. A separate announcement will be made when the share capital
increase has been registered.


IMPORTANT INFORMATION

This announcement is not an offer to sell or a solicitation of offers to
purchase or subscribe for shares. Copies of this announcement may not be sent
to jurisdictions, or distributed in or sent from jurisdictions, in which this
is barred or prohibited by law. The information contained herein shall not
constitute an offer to sell or the solicitation of an offer to buy, in any
jurisdiction in which such offer or solicitation would be unlawful absent
registration, or an exemption from registration or qualification under the
securities laws of any jurisdiction.

This document is not for publication or distribution in, directly or
indirectly, Australia, Canada, Japan, Hong Kong, South Africa or the United
States or any other jurisdiction in which such release, publication or
distribution would be unlawful, and it does not constitute an offer or
invitation to subscribe for or purchase any securities in such countries or in
any other jurisdiction. In particular, the document and the information
contained herein should not be distributed or otherwise transmitted into the
United States or to publications with a general circulation in the United
States of America.

This announcement is not an offer for sale of securities in the United States.
Securities may not be offered or sold in the United States absent registration
with the United States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the
"Securities Act"). The Company does not intend to register any part of the
offering in the United States or to conduct a public offering in the United
States of the shares to which this document relates. This announcement is for
information purposes only and is not to be relied upon in substitution for the
exercise of independent judgment. It is not intended as investment advice and
under no circumstances is it to be used or considered as an offer to sell, or
a solicitation of an offer to buy any securities or a recommendation to buy or
sell any securities of the Company.

This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect
current expectations and assumptions as to future events and circumstances
that may not prove accurate. A number of material factors could cause actual
results and developments to differ materially from those expressed or implied
by these forward-looking statements.

The Company expressly disclaims any obligation or undertaking to update,
review or revise any statement contained in this announcement whether as a
result of new information, future developments or otherwise.

Contacts
Kristian Flaten
CEO & CFO
Aqua Bio Technology ASA

Phone: +47 9509 2322
Email: kf@aquabiotech.no

About Us
Aqua Bio Technology ASA (ABTEC) is a technology and distribution group in
skincare and nonfood. The group has distribution towards B2C and B2B, and
offers freight, customs, and logistics services. The group also develops
sustainable biotechnology for use in skincare products. Aqua Bio Technology is
listed on Euronext Expand Oslo.

This notice is published by Kristian Flaten on the listed date and time.

This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR. The information was submitted for publication, through the
agency of the contact persons set out above, at 2026-03-20 15:20 CET.

More information:
Access the news on Oslo Bors NewsWeb site

669016_Aqua Bio Technology ASA- Preliminary results of the Subsequent Offering.pdf